Yunanistan - Yunanca - Εθνικός Οργανισμός Φαρμάκων

meditrina ΕΠΕ Ηρακλείτου 117,, 152 38 152 38, Χαλάνδρι 210.6726260 - prulifloxacin - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - 600mg/tab - prulifloxacin 600mg - prulifloxacin

Avrupa Birliği - Yunanca - EMA (European Medicines Agency)

viatris limited - κλοπιδογρέλη besilate - peripheral vascular diseases; stroke; myocardial infarction - Αντιθρομβωτικοί παράγοντες - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). Υψόμετρο τμήμα του st οξύ έμφραγμα του μυοκαρδίου, σε συνδυασμό με ΑΣΟ σε ιατρικά ασθενών επιλέξιμων για θρομβολυτική θεραπεία. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. Για περαιτέρω πληροφορίες ανατρέξτε στην παράγραφο 5.

Avrupa Birliği - Yunanca - EMA (European Medicines Agency)

taw pharma (ireland) limited - υδροχλωρική κλοπιδογρέλη - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - Αντιθρομβωτικοί παράγοντες - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Yunanistan - Yunanca - Εθνικός Οργανισμός Φαρμάκων

sandoz gmbh, kundl, austria (0000005735) biochemiestrasse 10,, a-6250, kundl - valsartan; hydrochlorothiazide - ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ - (80+12,5)mg/tab - 0137862534 valsartan 80.000000 mg; 0000058935 hydrochlorothiazide 12.500000 mg - valsartan and diuretics

Yunanistan - Yunanca - Εθνικός Οργανισμός Φαρμάκων

sandoz gmbh, kundl, austria (0000005735) biochemiestrasse 10,, a-6250, kundl - valsartan; hydrochlorothiazide - ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ - (160+12.5)mg/tab - 0137862534 valsartan 160.000000 mg; 0000058935 hydrochlorothiazide 12.500000 mg - valsartan and diuretics

Yunanistan - Yunanca - Εθνικός Οργανισμός Φαρμάκων

sandoz gmbh, kundl, austria (0000005735) biochemiestrasse 10,, a-6250, kundl - valsartan; hydrochlorothiazide - ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ - (160+25)mg/tab - 0137862534 valsartan 160.000000 mg; 0000058935 hydrochlorothiazide 25.000000 mg - valsartan and diuretics

Yunanistan - Yunanca - Εθνικός Οργανισμός Φαρμάκων

sandoz gmbh, kundl, austria (0000005735) biochemiestrasse 10,, a-6250, kundl - valsartan; hydrochlorothiazide - ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ - (320+12,5)mg/tab - 0137862534 valsartan 320.000000 mg; 0000058935 hydrochlorothiazide 12.500000 mg - valsartan and diuretics

Yunanistan - Yunanca - Εθνικός Οργανισμός Φαρμάκων

sandoz gmbh, kundl, austria (0000005735) biochemiestrasse 10,, a-6250, kundl - valsartan; hydrochlorothiazide - ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ - (320+25)mg/tab - 0137862534 valsartan 320.000000 mg; 0000058935 hydrochlorothiazide 25.000000 mg - valsartan and diuretics

Güney Kıbrıs Rum Kesimi - Yunanca - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

sandoz gmbh - ΥΔΡΟΧΛΩΡΟΘΕΙΑΖΊΔΗ, micronized, ΤΗΣ ΒΑΛΣΑΡΤΆΝΗΣ - film coated tablets - 160mg/25mg - 8000003541 - hydrochlorothiazide, micronized - 25 mg; 8000001531 - valsartan - 160 mg - valsartan

Güney Kıbrıs Rum Kesimi - Yunanca - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

sandoz gmbh - ΥΔΡΟΧΛΩΡΟΘΕΙΑΖΊΔΗ, micronized, ΤΗΣ ΒΑΛΣΑΡΤΆΝΗΣ - film coated tablets - 320mg/25mg - 8000003541 - hydrochlorothiazide, micronized - 25 mg; 8000001531 - valsartan - 320 mg - valsartan